Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant Charcot-Marie-Tooth disease type 2L (CMT2L) is a form of axonal Charcot-Marie-Tooth disease, a peripheral sensorimotor neuropathy. In the single family reported to date, CMT2L onset is between 15 and 33 years. Patients present with a symmetric distal weakness of legs and occasionally of the hands, absent or reduced tendon reflexes, distal legs sensory loss and frequently a pes cavus. Progression is slow.
Features include always present findings: Decreased number of large peripheral myelinated nerve fibers and Decreased amplitude of sensory action potentials; and common findings: Pes cavus. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 2 | Hyporeflexia, Peripheral axonal neuropathy |
Bones and joints | 1 | Sideways curvature of the spine (scoliosis) |
Muscles | 1 | Distal muscle weakness |
HSPB8 encodes heat shock protein family B (small) member 8 (196 aa). Involved in the chaperone-assisted selective autophagy (CASA), a crucial process for protein quality control, particularly in mechanical strained cells and tissues such as muscle. Highest expression in Esophagus Muscularis (583.2 TPM) and Colon Sigmoid (522.6 TPM).
Charcot-Marie-Tooth disease axonal type 2L is associated with mutations in the HSPB8 gene on chromosome 12.
HSPB8 is classified as a druggable target (Kinase and Serine Threonine Kinase categories) with score 0.0.
Genetic testing for HSPB8 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 2 always present features, 1 common feature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
2 clinical trials registered, 2 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
9 publications have been identified in PubMed for Charcot-Marie-Tooth disease axonal type 2L. Research spans Review / Meta-Analysis (44%), Basic Science / Preclinical (33%), and Case Report / Case Series (11%).
Bjelica B (2026). [PMID: 41549766](https://pubmed.ncbi.nlm.nih.gov/41549766/). *J Peripher Nerv Syst*. [Case Report / Case Series]
Putko BN (2026). [PMID: 41426051](https://pubmed.ncbi.nlm.nih.gov/41426051/). *Neurol Genet*. [Basic Science / Preclinical]
Zhou W (2026). [PMID: 41951012](https://pubmed.ncbi.nlm.nih.gov/41951012/). *Biochim Biophys Acta Mol Basis Dis*. [Review / Meta-Analysis]
Rashed HR (2025). [PMID: 40243504](https://pubmed.ncbi.nlm.nih.gov/40243504/). *Int J Mol Sci*. [Review / Meta-Analysis]
Vendredy L (2025). [PMID: 39972648](https://pubmed.ncbi.nlm.nih.gov/39972648/). *J Gene Med*. [Basic Science / Preclinical]
Sisto A (2025). [PMID: 39698979](https://pubmed.ncbi.nlm.nih.gov/39698979/). *Autophagy*. [Basic Science / Preclinical]
Alhazmi AS (2025). [PMID: 41290347](https://pubmed.ncbi.nlm.nih.gov/41290347/). *Neurosciences (Riyadh)*. [Epidemiology / Natural History]
Tazir M (2024). [PMID: 38702287](https://pubmed.ncbi.nlm.nih.gov/38702287/). *Rev Neurol (Paris)*. [Review / Meta-Analysis]
Isik FI (2024). [PMID: 39737171](https://pubmed.ncbi.nlm.nih.gov/39737171/). *Front Immunol*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 18, 2026, 7:03 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease axonal type 2L